Suppression of neuroinflammation in forebrain-specific Cdk5 conditional knockout mice by PPARγ agonist improves neuronal loss and early lethality by Elias Utreras et al.
JOURNAL OF 
NEUROINFLAMMATION
Utreras et al. Journal of Neuroinflammation 2014, 11:28
http://www.jneuroinflammation.com/content/11/1/28RESEARCH Open AccessSuppression of neuroinflammation in
forebrain-specific Cdk5 conditional knockout
mice by PPARγ agonist improves neuronal loss
and early lethality
Elias Utreras1,4, Ryusuke Hamada2, Michaela Prochazkova1, Anita Terse1, Satoru Takahashi3, Toshio Ohshima2*
and Ashok B Kulkarni1*Abstract
Background: Cyclin-dependent kinase 5 (Cdk5) is essential for brain development and function, and its deregulated
expression is implicated in some of neurodegenerative diseases. We reported earlier that the forebrain-specific Cdk5
conditional knockout (cKO) mice displayed an early lethality associated with neuroinflammation, increased
expression of the neuronal tissue-type plasminogen activator (tPA), and neuronal migration defects.
Methods: In order to suppress neuroinflammation in the cKO mice, we first treated these mice with pioglitazone, a
PPARγ agonist, and analyzed its effects on neuronal loss and longevity. In a second approach, to delineate the
precise role of tPA in neuroinflammation in these mice, we generated Cdk5 cKO; tPA double knockout (dKO) mice.
Results: We found that pioglitazone treatment significantly reduced astrogliosis, microgliosis, neuronal loss and
behavioral deficit in Cdk5 cKO mice. Interestingly, the dKO mice displayed a partial reversal in astrogliosis, but they
still died at early age, suggesting that the increased expression of tPA in the cKO mice does not contribute
significantly to the pathological process leading to neuroinflammation, neuronal loss and early lethality.
Conclusion: The suppression of neuroinflammation in Cdk5 cKO mice ameliorates gliosis and neuronal loss, thus
suggesting the potential beneficial effects of the PPARγ agonist pioglitazone for the treatment for
neurodegenerative diseases.
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Cyclin-dependent kinase 5 (Cdk5) is an atypical member
of the cyclin-dependent kinase family, whose other mem-
bers are key regulators of the cell cycle [1]. Cdk5 is ubiqui-
tously expressed, and it is mainly active in post-mitotic
neurons, where its activators p35 and p39 are predomin-
antly expressed [2,3]. Cdk5 is a proline-directed serine/
threonine kinase that phosphorylates a consensus sequence
of (S/T)PX(K/H/R) in many target proteins [4]. Cdk5* Correspondence: ohshima@waseda.jp; ak40m@nih.gov
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stated.phosphorylates many cytoskeletal elements, signaling mol-
ecules, ions channels, nociceptors and regulatory proteins
that participate in the normal function of the brain and
also during neurodegenerative disorders [1,3,5,6]. A de-
tailed analysis of Cdk5 knockout mice, which display peri-
natal lethality and extensive neuronal migration defects,
revealed that Cdk5 serves as key regulator of neuronal
migration, neurite outgrowth, axonal pathfinding and den-
drite development [7,8]. To circumvent the perinatal le-
thality of Cdk5 knockout mice, we previously generated
Cdk5 conditional knockout (cKO) mice that lacked Cdk5
expression in the forebrain [9,10]. At three months of age,
these mice displayed an early lethality associated with neu-
roinflammation, increased expression of the neuronal
tissue-type plasminogen activator (tPA) and tumor necrosisLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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has been reported to effectively suppress neuroinflamma-
tion in an Alzheimer’s disease (AD) mouse model [11] and
it also had beneficial effects in mouse models of multiple
sclerosis (ALS) [12-15] and Parkinson’s disease (PD) [16],
we treated cKO mice with pioglitazone, and analyzed its ef-
fects on longevity, neuronal loss, and studied the timing of
activation of astrocytes and microglial cells by using im-
munofluorescence against anti-GFAP and Iba1, respect-
ively. In a second approach, we generated Cdk5 and tPA
double knockout (dKO) mice to observe effects of the
loss of tPA expression on neuroinflammation, astroglio-
sis and longevity. Our studies revealed the beneficial
effects of pioglitazone treatment on the cKO mice.
However, the loss of tPA expression in the forebrain of
the cKO mice did not ameliorate neuroinflammation
and early lethality in these mice.
Methods
Animals and experimental protocols
Cdk5f/f mice [9] were crossed with CamKII-Cre+ trans-
genic mice [17] to delete Cdk5, specifically in forebrain
adult neurons and these mice were named Cdk5 cKO1
mice [10]. To avoid possible effects of Cre-mediated dele-
tion of the noncoding sequence of flanking genes located
in the proximity of Cdk5 gene, Accn3 and Slc4a2, in Cdk5
cKO1 mice, we crossed Cdk5f/-, Cdk5+/− [7], and CamKII-
Cre+ mice to generate Cdk5f/-; CamKII-Cre+ mice, named
Cdk5 cKO2 mice [10]. Additionally, we crossed tPA
knockout mice [18] with Cdk5 cKO2 mice to generate
double knockout mice: Cdk5 cKO; tPA KO named dKO
mice (Additional file 1: Figure S1). The genotype of each
mouse was determined by the PCR from DNA obtained
from tail biopsies. These studies were performed in com-
pliance with the National Institutes of Health Guidelines
on the Care and Use of Laboratory and Experimental
Animals. All experimental procedures were approved by
the Animal Care and Use Committee of the National In-
stitute of Dental and Craniofacial Research, NIH and
the Waseda University.
Antibodies and materials
Anti-NeuN mouse monoclonal antibody (clone A60,
1:500, Chemicon, Temecula, CA, USA), anti-GFAP rabbit
polyclonal antibody (1:500, Dako, Carpinteria, CA, USA),
and anti-Iba1 rabbit polyclonal antibody (1:500, Wako,
Richmond, VA, USA), and anti-Cdk5 (308-CDK5 Phos-
phosolutions, Aurora, CO, USA) were used for immuno-
histochemical analysis of Cdk5 cKO and control mice.
Anti-Cdk5 (C8 and J3), anti-p35 (C19), and secondary
antibodies (HRP-conjugated goat anti-mouse, anti-rabbit
antibodies) from Santa Cruz Biotechnology, Inc. (Santa
Cruz, CA, USA), GFAP antibody from Cell Signaling
Technology (Beverly, MA, USA), anti-NeuN antibodyfrom Millipore (Temecula, CA, USA), histone H1 and α-
tubulin antibody from Sigma (St. Louis, MO, USA) were
used for the Western blot analysis of Cdk5 cKO2 and
control mice.
PPARγ agonist pioglitazone treatment
Pioglitazone hydrochloride was obtained from TOCRIS
Bioscience (Bristol, UK). The mice were fed rodent chow
ad libitum that was supplemented with 350 ppm pioglit-
azone hydrochloride from P30. The final dosage of the
drug was calculated to 58.3 mg/kg/day of pioglitazone
based on an average daily food consumption of 5 g of
chow per mouse.
Histological analyses
After intraperitoneal injections of avertin (250 mg/kg,
Sigma, St. Louis, MO, USA) mice were transcardially
perfused with freshly prepared 4% paraformaldehyde in
0.1 mol/L cacodylate buffers, pH 7.4 and brains were re-
moved and embedded in a gelatin matrix (NeuroScience
Associates, Knoxville, TN, USA). Free-floating sections
(35 μm in thickness) were cut on a microtome and proc-
essed for staining. Histological analyses with cresyl violet
(Nissl stain, Molecular Probe, Eugene, OR, USA), amino-
cupric staining, and immunohistochemistry against anti-
NeuN (Chemicon, Temecula, CA, USA) and anti-GFAP
(DAKO, Glostrup, Denmark) were performed as previously
described [10]. The staining specificity of these antibodies
was assessed by omission of the primary antibodies.
Immunohistochemistry
Cdk5 cKO1 and control mice were perfusion-fixed with
4% paraformaldehyde; thereafter, their brains were re-
moved from their skulls and immersed in the same fixa-
tive, which was done overnight at 4°C. The brains were
then equilibrated in 20% sucrose and embedded in an
optimal cutting temperature (OCT) compound. Cryosec-
tions of 14-μm thickness were cut with a frozen micro-
tome. The immunostaining of sections was performed as
previously described [8]. Briefly, after the blocking of a
non-specific binding of antibodies, the sections were in-
cubated with the primary antibodies, which were diluted
in PBS/0.01% Triton X-100, overnight at 4°C. They were
then washed three times with PBS and incubated with
Alexa-Fluor 488 (1:1,000) or Alexa-Fluor 568 (1:1,000)
(Molecular Probes, Eugene, OR, USA) secondary anti-
bodies for one hour. After three further washes with PBS,
the sections were embedded in Vectashield mounting
media (Vector, Burlingame, CA, USA). Images were ob-
tained by a CCD camera (DP70, Olympus).
Cell count
Neurons, activated astrocytes and microglia were counted
in coronal brain sections. All labeled cells within three
Utreras et al. Journal of Neuroinflammation 2014, 11:28 Page 3 of 12
http://www.jneuroinflammation.com/content/11/1/28squares of 0.15 mm2 each were counted in coronal sec-
tions using a BX-51 Olympus (Tokyo, Japan) microscope
(200× magnification: 10× ocular and 20× objective) as de-
scribed [19]. Six sections from each brain were analyzed
and averaged. The mean value from the combined data of
at least three animals per time point was calculated. To
exclude false-positives, only GFAP- or Iba1-positive
signals merged with nuclear staining by diamidino-2-
phenylindole (DAPI) staining were counted.
Neuronal size
To evaluate neuronal size, we stained coronal sections
from these mice with NeuroTrace™ 530/615 (red fluores-
cent Nissl stain from Molecular Probe, Eugene, OR, USA)
and DAPI. Images were obtained by a confocal micro-
scope (FV1000, Olympus, Tokyo, Japan). Sizes of CA1
pyramidal neurons (more than 50 neurons from three
mice) were measured by Image-J.
Western blot analysis
Protein extracts were obtained from brain cortex of
control, Cdk5 cKO2, and dKO mice at P17 in T-PER
buffer (Pierce, Rockford, IL, USA) with protease inhibi-
tor cocktail tablets and phosphatase inhibitor cocktail
tablets, PhosSTOP (Roche Diagnostic, Indianapolis, IN,
USA), and Western blot analyses were performed as
previously reported [20]. Protein concentration of the
supernatant was determined using the Bradford Protein
Assay (Bio-Rad, Hercules, CA, USA). Proteins were sepa-
rated in 4 to 12% or 3 to 8% SDS-PAGE gels and trans-
ferred to nitrocellulose membranes (Invitrogen, Carlsbad,
CA, USA). The membranes were soaked in a blocking
buffer (5% nonfat dry milk in PBS with 0.05% Tween-20
(PBST)) for one hour at room temperature, and then incu-
bated overnight at 4°C, with the appropriate primary anti-
body diluted in the blocking buffer. The membranes were
washed in PBST and incubated for one hour at room
temperature with the secondary antibodies diluted in
blocking buffer. Immunoreactivity was detected by Super-
Signal West Pico or Dura Chemiluminescent Substrate
(Thermo Scientific, Rockford, IL, USA). Membranes were
stripped for 15 minutes at room temperature with Re-blot
Plus Strong Solution (Chemicon, Temecula, CA, USA).
They were retested with α-tubulin antibodies to normalize
for protein loading. The optical densities of the bands
were quantified using an image analysis system with
Scion Image Alpha 4.0.3.2 software (Scion Corporation,
Frederick, MD, USA).
Cdk5 kinase activity assay
As reported earlier, 300 μg of protein from brain cortex
of 17-day-old control, Cdk5 cKO2, and dKO mice, were
dissolved in T-PER buffer, and they were immunopreci-
pitated using 4 μg of anti-Cdk5 (C8) antibody (SantaCruz Biotechnology, Inc., Santa Cruz, CA, USA) [21].
Immunoprecipitated proteins (IP) were washed three
times in cold PBS, and twice in kinase buffer (20 mM
Tris HCl (pH 7.4), 10 mM MgCl2, 1 mM EDTA). Then,
the IP was mixed with the kinase assay mixture (100 mM
Tris HCl (pH 7.4), 50 mM MgCl2, 5 mM EDTA, and
5 mM DTT) plus 5 units of (γP32)-ATP, and using 5 μg of
histone H1 as a substrate. The kinase assays were carried
out for 30 minutes at 30°C, and the kinase activity reaction
was stopped by adding 5× sodium dodecyl sulfate sample
buffer and boiling for ten minutes at 70°C. Kinase reaction
was electrophoresed on a 4 to 20% polyacrylamide gel,
and then gels were exposed to X-ray films, for 1 to
3 hours at −80°C. The incorporation of P32 to histone
H1 was quantified to measure band intensity using
Scion Image Alpha 4.0.3.2 software (Scion Corporation,
Frederick, MD, USA).
RNA isolation and real-time PCR
Total RNAs were obtained from brain cortex of 17-day-
old control, Cdk5 cKO2, and dKO mice. RNA was isolated
from tissue using TRIzol® reagent (Invitrogen, Carlsbad,
CA, USA), according to the manufacturer’s instructions.
Following TURBO DNA-free (Ambion, Austin, TX, USA)
digestion of the total RNA sample, oligo (dT)-primed
synthesis of cDNA from 3 μg of total RNA was made
using SuperScript™ III Reverse Transcriptase (Invitrogen,
Carlsbad, CA, USA) to remove contaminated genomic
DNA. For detection of CD68, TNF-α, interleukin 6 (IL-6),
interferon-γ (IFN-γ), interleukin 1β (IL-1β), transforming
growth factor β1 (TGF-β1), oncostatin M (OSM) and
leukemia inhibitory factor (LIF) mRNA, we used real-time
PCR, and the following reaction mixture was used for
these PCR samples: 1xIQ™ Sybr®Green Super Mix (Bio-
Rad, Hercules, CA, USA), 100 to 200 nM of each primer
and 1 μl of cDNA. cDNA was amplified and analyzed in
triplicate using Opticon Monitor Chromo 4 (Bio-Rad,
Hercules, CA, USA). The following primers were used to
amplify and measure the amount of mouse mRNA by
real-time PCR: CD68 sense 5′-ACC GCC ATG TAG TCC
AGG TA-3′ and antisense 5′-ATC CCC ACC TGT CTC
TCT CA-3′; Cdk5 sense 5′-GGC TAA AAA CCG GGA
AAC TC-3′ and Cdk5 antisense 5′-CCA TTG CAG CTG
TCG AAA TA-3′; TNF-α sense 5′-GAT CTC AAA GAC
AAC CAA CTA GT-3′ and antisense 5′-CTC CAG CTG
GAA GAC TCC TCC CAG -3′; IL-6 sense 5′-CTG CAA
GAG ACT TCC ATC CAG TT -3′ and antisense 5′-GAA
GTA GGG AAG GCC GTG G -3′; IFN-γ sense 5′-TCA
AGT GGC ATA GAT GTG GAA GAA-3′ and antisense
5′-TGG CTC TGC AGG ATT TTC ATG-3′; IL-1β sense
5′-CAA CCA ACA AGT GAT ATT CTC CAT G-3′ and
antisense 5′-GAT CCA CAC TCT CCA GCT GCA-3′,
TGF-β1 sense 5′-GCA GTG GCT GAA CCA AGG AG-
3′ and antisense 5′–CCC GAC GTT TGG GGC TGA
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TAC-3′ and antisense 5′-GAA GGT CTG ATT TTG
CGG GAT-3′; LIF sense 5′-ACG GCA ACC TCA TGA
ACC A-3′ and antisense 5′-GGA AAC GGC TCC CCT
TGA-3′. The gene expression level was normalized
against S29 expression using S29 sense 5′-GGA GTC
ACC CAC GGA AGT TCG G-3′ and antisense 5′-GGA
AGC ACT GGC GGC ACA TG-3′. Real-time PCR re-
actions were run in triplicate and repeated three times.
Statistical analysis
All of the experiments were performed a minimum of
three times. The statistical evaluation was done with
GraphPad Prism software, version 4.0 (GraphPad, San
Diego, CA, USA). The significant differences between
the experiments were assessed by univariate ANOVA
(more than two groups) or unpaired t-tests (two groups).
ANOVA was followed by t-tests using a Bonferroni α-
correction or Dunett’s test, where α was set to 0.05.
Results
Inflammatory reactions precede neuronal loss and early
lethality in Cdk5 cKO mice
As reported earlier, we generated two lines of Cdk5 con-
ditional knockout mice: Cdk5 cKO1 (Cdk5f/f; CamKII-
Cre+) and Cdk5 cKO2 (Cdk5f/-, CamKII-Cre+) mice [10]
(see, Additional file 1: Figure S1). Both Cdk5 cKO1 and
cKO2 mice were born with an expected Mendelian fre-
quency. As described earlier [10] 20% to 30% of Cdk5
cKO1 mice lived for more than three months; however
95% of the Cdk5 cKO2 mice died within one month
after birth. We had earlier observed that the neuroin-
flammation and neuronal loss occurred at P90 but not at
P21 in Cdk5 cKO1 mice as compared to Cdk5f/f controls
[10]. To define the precise timing of the onset of this
neuroinflammation, we analyzed the inflammatory reac-
tions in the brain of Cdk5 cKO1 mice by immunohisto-
chemical staining. NeuN, GFAP and Iba1 were used as
markers for neurons, activated astrocytes and microglia,
respectively. At P21, we did not notice any increase in the
GFAP-positive or Iba1-positive cells (Additional file 2:
Figure S2A-E). At P30, we observed increased GFAP-
positive cells and Iba1-positive cells in the brain cortex of
Cdk5 cKO1 mice (Additional file 2: Figure S2F-J); how-
ever, there was no apparent decrease in the NeuN-positive
cells, thus indicating that neuronal loss did not occur at
this age. Moreover, we evaluated whether the deficient of
Cdk5 in mice produced pathological changes such as de-
generative neurons or change in neuron size. We analyzed
different areas of control and Cdk5 cKO1 mice at P30 and
we performed amino-cupric silver and Nissl stain to evalu-
ate those parameters. We found an increased number of
amino-cupric silver positive cells in both cerebral cortex
and striatum of Cdk5 cKO1 as compared with controlmice (Additional file 3: Figure S3A). At this stage, no
difference in neuronal size was found in CA1 pyramidal
neurons between Cdk5 cKO1 and control littermates
(Additional file 3: Figure S3B).
Pioglitazone, PPARγ agonist, treatment improved
neuronal loss in Cdk5 cKO1 mice
Because we observed neuroinflammation in the Cdk5
cKO1 cortex at P30, we hypothesized that the inflamma-
tory reactions were the cause of neuronal loss [10]. To
test this hypothesis, we treated the Cdk5 cKO1 mice
with the PPARγ agonist pioglitazone that suppressed in-
flammation in the brain of an AD mouse model [11].
We started the pioglitazone treatment at P30 and ana-
lyzed the results of this treatment at P60 and P90. We
compared the survival of the treated and untreated Cdk5
cKO1 mice. At P60, 76% of the Cdk5 cKO1 mice (16/
21) survived as compared to 33% of the untreated mice
(13/39) (P < 0.01; P = 0.0080 in Log-rank test and P =
0.0086 in Wilcoxon test) (Figure 1A). At P90, a similar
higher survival rate was observed in the treated Cdk5
cKO1 mice (Additional file 4: Figure S4A). We next com-
pared the body weight gain in the male mice from both the
groups. At P60, untreated Cdk5 cKO1 mice showed re-
duced body weight whereas the treated Cdk5 cKO1 mice
recovered from the body weight loss (control = 23.62 ±
0.68 g, untreated Cdk5 cKO1 mice = 17.79 ± 1.11 g, and
treated Cdk5 cKO1 mice = 21.79 ± 0.53 g) (Figure 1B).
Improved body weight gain was also observed in the
treated Cdk5 cKO1 mice at P90 (Additional file 4: Figure
S4B). Since we had earlier observed neuronal loss in the ol-
factory bulb, brain cortex, striatum and hippocampus of
Cdk5 cKO1 mice at P90 [10], we analyzed cell densities of
neurons, reactive astrocytes and microglia by using NeuN,
GFAP, and Iba1 markers, respectively. At P60, we observed
significant neuronal loss in all regions in the untreated
Cdk5 cKO1 mice, whereas neuronal loss was significantly
reversed in the treated Cdk5 cKO1 mice (Figure 1C-E).
We also found a decrease in the number of GFAP-
positive astrocytes and Iba1-positive microglia in the
treated Cdk5 cKO1 mice, as compared to the untreated
mice (Figure 1C-G). Improvement in neuronal loss and
suppressed neuroinflammation were also found in the
treated Cdk5 cKO1 mice at P90 (Additional file 4:
Figure S4C-G). The data indicate that pioglitazone sup-
pressed neuroinflammation and partially rescued neuronal
loss in Cdk5 cKO1 mice, suggesting that neuroinflamma-
tion caused neuronal loss in the Cdk5 cKO1 mouse brain.
As described previously [10], untreated Cdk5 cKO1 mice
showed retraction of their limbs toward their trunks when
suspended by their tail. Therefore, we analyzed whether
pioglitazone treatment can improve the neurological def-
icit observed in Cdk5 cKO1 mice. We found that this
phenotype was partially improved in treated Cdk5 cKO1
Figure 1 PPARγ agonist pioglitazone suppressed inflammation and partially reversed neuronal loss in Cdk5 cKO1 mice. (A) Survival
curves for untreated and treated Cdk5 cKO1 mice from P30 to P60. Survival rate for treated mice (n = 16) is better than that of untreated mice
(n = 13). (B) Average body weights of untreated (n = 3) and treated (n = 3) male Cdk5 cKO1 mice and littermate male Cdk5f/f (control) mice
(n = 3) at P60. *P < 0.05. (C), (D) Immunohistochemical (IHC) analyses of control, untreated, and treated Cdk5 cKO1 mice in cerebral cortex (C) and
hippocampus (D) at P60. Coronal sections from these mice were stained with antibodies for NeuN, GFAP and Iba1. Scale bar = 100 μm. (E-G) Bar
graphs indicate average cell densities of neurons (E), activated astrocytes (F) and microglia cells (G) in control, untreated and treated Cdk5 cKO1
mice at P60. ***P < 0.001 between control versus Cdk5 cKO1. †P < 0.05; ‡P < 0.01; §P < 0.001 between no treated versus treated (t-test).
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at P60 (Additional file 5: Movie S1).
Decreased Cdk5 and p35 protein expression and Cdk5
kinase activity in brain of Cdk5 cKO2 and dKO mice
To generate Cdk5 cKO; tPA KO mice (dKO), we crossed
Cdk5 cKO2 (Cdk5f/-; CamKII-Cre+) with tPA knockout
mice (tPA−/−) (Additional file 1: Figure S1). Both Cdk5
cKO2 and dKO mice were born with an expectedMendelian frequency. Both Cdk5 cKO2 and dKO mice
were indistinguishable from the control littermates at
birth although some of the Cdk5 cKO2 and dKO mice
were born dead. Surprisingly, we observed that nearly
95% of dKO mice died within a week after weaning (P21),
similar to the trend we observed in Cdk5 cKO2 [10]. We
measured their body weights at P17 and found a signifi-
cant decrease in body weight gain in the Cdk5 cKO2 and
dKO mice as compared to the control mice. Interestingly,
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comparison to the Cdk5 cKO2 mice suggesting a partial
rescue in body weight loss in the dKO mice (Figure 2A
and B). On the other hand, tPA KO mice did not show
any changes in survival rate and body weight gain in com-
parison with the control mice (data not shown).
We analyzed the Cdk5 mRNA levels in the brain cor-
tex of P17 mice by using real-time PCR. We found that
Cdk5 mRNA levels were significant decreased in both
Cdk5 cKO2 and dKO mice as compared to the control
mice (Figure 3A). Interestingly, Cdk5 mRNA levels of the
dKO mice were significantly higher in comparison to the
Cdk5 cKO2 mice, suggesting a partial rescue (Figure 3A).
Additionally, we analyzed Cdk5 protein levels in the brain
cortex of P17 mice by using Western blot analysis. Cdk5
protein levels were significantly decreased in both Cdk5
cKO2 and dKO mice as compared to the control mice
(Figure 4A). Also, we performed IHC against Cdk5 and
we found decreased expression of Cdk5 in neurons in the
cortex of Cdk5 cKO2 and dKO mice as compared with
control mice at P17 (black and blue arrow head Figure 3B
left panel) suggesting that remaining Cdk5 positive cells
observed in Cdk5 cKO2 and dKO were the glial cells or
neuron cells in which Cre-mediated recombination was
absent. Additionally, we analyzed the p35 protein levels by
Western blot and found a significantly reduced expression
in both Cdk5 cKO2 and dKO mice as compared with the
control mice. Remarkably, the p35 protein levels were
significantly higher in dKO, in comparison with those in
Cdk5 cKO2 mice, suggesting again a partial rescue in
dKO mice (Figure 4B). Since the p35 expression is a limit-
ing factor for Cdk5 kinase activity [22], we determined
whether Cdk5 kinase activity was affected in the brain cor-
tex of mice at P17. We found a significant decrease in
Cdk5 kinase activity in cKO2 and dKO mice, as compared
with the control mice. Interestingly, Cdk5 kinase activity
was significantly higher in dKO in comparison with theFigure 2 Generation of Cdk5 cKO2; tPA KO (dKO) mice. (A) Body weig
images of control, tPA KO, Cdk5 cKO2 and dKO mice. All data are presente
***P < 0.001 (t-test).Cdk5 cKO2 mice, suggesting a partial rescue in the dKO
mice (Figure 4C).
Increased neuronal loss and reduced astrogliosis in brain
of dKO mice
We earlier reported that Cdk5 cKO2 mice displayed
neuronal loss and increased astrogliosis as determined
by the NeuN and GFAP protein levels, respectively [10].
To evaluate whether tPA deficiency in the background
of Cdk5 cKO2 mice could improve this phenotype, we
analyzed neuronal loss as detected by Nissl staining and
NeuN expression, and astrogliosis detected by GFAP
protein expression in coronal brain sections of control,
Cdk5 cKO2, and dKO mice at P17. We found that both
Cdk5 cKO2 and dKO mice showed a decreased Nissl
staining (Figure 5A) and also a reduced NeuN expres-
sion measured by IHC (Figure 5B) as compared with the
control mice. In addition, we found significantly de-
creased NeuN protein levels in both Cdk5 cKO2 and
dKO brain cortex, as compared with the controls at P17
(Figure 5D). We also evaluated astrogliosis by IHC and
the Western blot of GFAP in these mice. As reported
earlier [10], we found increased GFAP staining by IHC;
and a significant increase in GFAP protein expression by
Western blot analysis in the brain cortex of Cdk5 cKO2
mice as compared with the control mice. Surprisingly,
the levels of GFAP in the dKO mice were reversed to
near normal levels (Figure 5C and E) suggesting a partial
reversal in the gliosis in these mice.
Increased microgliosis and pro-inflammatory cytokines in
the brain of dKO mice
We had reported earlier increased microglia activation
measured by F4/80 marker and CD68 mRNA levels in the
forebrain of Cdk5 cKO1 mice at two to three months old
[10]. To extend these observations to the Cdk5 cKO2 and
dKO mice, we evaluated the CD68 mRNA levels and Iba1hts of 17-day-old mice of four different genotypes. (B) Representative
d as the mean and SEM (n = 6 to 12 mice per group),
Figure 3 Increased microgliosis and pro-inflammatory cytokines in the brain of dKO mice. (A) qPCR analysis of Cdk5 and CD68 mRNA
levels (a marker of activated microglia) normalized against S29. Total RNA was obtained from brain cortex of control, Cdk5 cKO2 and dKO mice at
P17. There was a decreased Cdk5 mRNA levels on Cdk5 cKO2 and dKO mice. In contrast, CD68 was increased only on dKO mice as compared
with control mice. (B) Right panel shows a representative IHC against Cdk5 and left panel an IHC against Iba1 of cortex coronal section from
control, Cdk5 cKO2 and dKO mice at P17. Decreased Cdk5 expression was observed in the cortex of Cdk5 cKO2 and dKO mice (Blue head arrows
as compared with black head arrows). IHC Iba1 shows that Iba1 positive cells are few in the cortex of the control mice as compared with Cdk5
cKO2 and dKO mice (red head arrows). Also, Iba1 positive cells are more apparent on dKO as compared with Cdk5 cKO2 mice. (C) Real-time PCR
analysis of mRNA levels of several pro-inflammatory cytokines normalized against S29. All data are presented as the mean and SEM (n = 3 to 5).
*P < 0.05; ***P < 0.001 (t-test).
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P17 the CD68 mRNA levels were similar in both the con-
trol and Cdk5 cKO2 mice. However, these levels were sig-
nificantly increased in dKO mice as compared with the
control and Cdk5 cKO2 mice (Figure 3A). Additionally,
we evaluated whether Cdk5 deletion in the brain cortex of
Cdk5 cKO2 and dKO mice could increase Iba1 positive
cells by using IHC (Figure 3B). We found that in the sameareas of the cortex of Cdk5 cKO2 mice where Cdk5 was
deleted (black and blue head arrow Figure 3B left panel),
there was an increase of Iba1 positive cells as compared
with control mice (red head arrow, Figure 3B right panel).
Remarkably, we found more Iba1 positive cells on cor-
tex of dKO mice as compared with Cdk5 cKO2 mice
suggesting increased microglial activation in the dKO
mice (Figure 3B right panel). As reported earlier, the
Figure 4 Decreased Cdk5 and p35 protein expression and Cdk5 activity in the brain of Cdk5 cKO2 and dKO mice. (A) Representative
Western blot analysis showing Cdk5 protein levels in brain cortex of control, Cdk5 cKO2 and dKO mice at P17. Lower panel showed a
quantification of Western blots for Cdk5. α-tubulin was used as loading control. (B) Representative Western blot analysis showing p35 protein
levels in brain cortex of control, Cdk5 cKO2 and dKO mice at P17. Lower panel showed a quantification of Western blots of p35. α-tubulin was
used as loading control. (C) Cdk5 kinase activity was measured from immunoprecipitates of proteins obtained from brain cortex of control, Cdk5
cKO2 and dKO mice at P17. All data are presented as the mean and SEM (n = 3 to 12). *P < 0.05, **P < 0.01, ***P < 0.001 (t-test).
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to three months old [10]. To extend these observations
to the Cdk5 cKO2 and dKO mice, we evaluated several
pro-inflammatory cytokines mRNA levels in the brain
cortex of control, Cdk5 cKO2 and dKO mice at P17. We
evaluated the expression of pro-inflammatory cytokines
such as TNF-α, IL-6, IFN-γ, IL-1β, TGF-β1, OSM, and LIF
in the brain cortices of mutant and control mice at P17.
Real-time PCR analysis with specific primers for all of the
indicated cytokines revealed that only TNF-α mRNA
levels were significantly increased, and OSM mRNA levels
were decreased in Cdk5 cKO2, as compared with the con-
trol mice (Figure 3C). Most importantly, we found that
mRNA levels of TNF-α, IL-6, IFN-γ, TGF-β1, and LIF
were significantly increased in the dKO mice as compared
with the control mice (Figure 3C), suggesting that in-
creased glial activation induced higher levels of cytokines
in dKO mice.
Discussion
The conditional deletion of neuronal Cdk5 in the adult
forebrain caused activation of astrocytes and microglia
and neuroinflammation, and a subsequent neuronal loss
and early lethality. In our first approach to suppress neu-
roinflammation in these mice, treatment with PPARγ
agonist pioglitazone resulted in a significant reduction in
microgliosis, astrogliosis, and neuronal loss associated
with a better survival rate. In the second approach, weevaluated the potential role of tPA in neuroinflammation
in Cdk5 cKO mice by generating dKO mice in which the
tPA gene was deleted. The deletion of tPA in the Cdk5 KO
mice caused a partial rescue in astrogliosis, although there
was increased microgliosis and inflammatory cytokines
levels. Nevertheless, the dKO mice still died at P21 similar
to the Cdk5 cKO2 mice, suggesting that tPA does not play
a major role in the etiology of neuroinflammation.
Differences in the longevity rate between the Cdk5
cKO1 and cKO2 mice are because the cKO2 mice have
significantly reduced Cdk5 protein levels, as compared
with Cdk5 cKO1 mice [10]. Cdk5 cKO2 mice have one
allele knocked out in all cells of the body whereas an-
other allele is deleted only in adult forebrain neurons.
However, in Cdk5 cKO1 mice both alleles are deleted
only in adult forebrain neurons, suggesting that expres-
sion levels of Cdk5 have a greater impact on the survival
rate of these mice. Our results confirm several earlier re-
ports indicating that Cdk5 kinase activity is required for
survival of neurons under stressful conditions [23-26].
Cdk5 is known to prevent neuronal apoptosis by nega-
tive regulation of JNK [23]. It is also involved in the
regulation of Akt activity mediating neuronal survival
[24]. Cdk5 also plays critical roles in non-neuronal cells,
such as oligodendrocytes and astrocytes. Thus, Cdk5
regulates oligodendrocytes differentiation and myelin re-
pair [27-30]. Moreover, it was shown that Cdk5/p35 is
expressed in astrocytes and it regulates the process of
Figure 5 Increased neuronal loss and partial rescue of astrogliosis in the brain of dKO mice. (A) Nissl staining of coronal brain sections of
control, Cdk5 cKO2 and dKO mice at P17. In higher magnification we observed a decreased of the number of cells on cortex and hippocampus
of Cdk5 cKO2 and dKO mice. (B) Immunohistochemistry (IHC) against NeuN, a marker of neurons, of coronal brain sections of control, Cdk5 cKO2
and dKO mice at P17. In higher magnification we observed a decreased of the number of NeuN positive cells on cortex and hippocampus of
Cdk5 cKO2 and dKO mice. (C) IHC against GFAP, a marker of astrogliosis, of coronal brain sections of control, Cdk5 cKO2 and dKO mice at P17. In
higher magnification we observed an increased number of GFAP positive cells on cortex and hippocampus of Cdk5 cKO2. In contrast, there were
a decreased number of GFAP positive cells on the same areas of brain of dKO mice. (D) Representative Western blot analysis showing NeuN
protein levels in brain cortex of control, Cdk5 cKO2 and dKO mice at P17. Lower panel showed a quantification of Western blots of NeuN.
α-tubulin was used as loading control. (E) Representative Western blot analysis showing GFAP protein levels in brain cortex of control, Cdk5
cKO2 and dKO mice at P17. Lower panel showed a quantification of Western blots of GFAP. α-tubulin was used as loading control. All data are
presented as the mean and SEM (n = 3 to 6). *P < 0.05 (t-test).
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neuroinflammation without neuronal loss at P30 in Cdk5
cKO1 mice. However, we observed pathological changes
in neurons by silver staining at P30, indicating that neuro-
inflammation might trigger neuronal degeneration, which
could be contributing to the neuronal loss at late stages.
Interestingly, we found an increased astrogliosis and neur-
onal loss much early in the cerebral cortex of Cdk5 cKO2
(P17) in comparison with Cdk5 cKO1 mice (P30), which
suggests that the decreased Cdk5 levels in Cdk5 cKO2
mice accelerate neuroinflammation with a consequent
neuronal loss and an early lethality.
PPARγ agonists inhibit the production of many in-
flammatory cytokines such as TNF-α, IL-1β and IL-6 in
several cell types, including monocytes, macrophages
and epithelial cells [32]. This inhibitory effect occurred
through silencing the action of the transcription factors,
NFκB and AP-1, on the promoters of the cytokines and
others genes [32-34]. On the other hand, microglia are
derived from hematopoietic precursors that enter the de-
veloping CNS to become a major population of resident
macrophages in brain. PPARγ agonists can potentially
control neuroinflammation through their actions on the
activated microglia which can produce, similar to periph-
eral macrophages, pro-inflammatory and neurotoxic fac-
tors, including cytokines, reactive oxygen intermediates,
and nitric oxide [35]. PPARγ agonist pioglitazone has been
reported to have beneficial effects on neurodegenerative
disease mouse models [36-38]. Thus, the pioglitazone
treatment seems to offer a broad range of potentially pro-
tective properties that attenuate the chronic neuroinflam-
mation and oxidative stress that is responsible for the
progression of PD [36]. Pioglitazone treatment also has
inhibitory effects on STAT3 activation in ALS mouse
models [37]. Additionally, it was reported that pioglita-
zone treatment of amyloid precursor protein/presenilin 1
mice (an AD mouse model) enhanced the microglial up-
take of Aβ and spatial cognitive memory improvement
[38]. Here, we have found that pioglitazone treatment
suppressed neuroinflammation by reducing activation of
microglia and astrocytes in Cdk5 cKO1 mice. Indeed, we
found that pioglitazone treatment can improve the neuro-
logical deficit observed in Cdk5 cKO1 mice. Similarly, the
survival rate and body weight gain was significantly in-
creased in the Cdk5 cKO1 mice treated with pioglitazone
as compared to the untreated Cdk5 cKO1 mice. These re-
sults suggest that a decrease in neuronal Cdk5 expression
produces an increased neuroinflammation, resulting in
neuronal loss and death.
In addition to the effects of PPARγ agonists on PPARγ
activity, it was recently demonstrated that troglitazone,
another PPARγ agonist, decreased tau-Thr231 phosphor-
ylation [39]. This repression was brought about by inhib-
ition of the Cdk5 kinase activity caused by an inhibition ofproteasomal degradation of p35 in human neuroblastoma
SH-SY5Y cells and rat primary cortical neurons in culture
[39]. Moreover, altered Cdk5 activity has been associated
with many neurodegenerative diseases, which is mainly
regulated by the increased proteolysis of p35 into p25,
with a subsequent increased Cdk5 kinase activity [40-42].
Therefore, the beneficial effects of PPARγ agonist treat-
ment in neurodegenerative diseases could be due to inhib-
ition of Cdk5 kinase activity and a subsequent reduction
in tau phosphorylation. Additionally, it will be of interest
to explore potential beneficial effects of these agonists for
treating painful disorders since Cdk5 has also been impli-
cated in pain signaling [6].
Two important questions that need to be answered are:
How microglia and astrocytes are activated? And which
molecules released from neurons are activating microglia
and astrocytes in Cdk5 cKO mice? In our previous work,
we found increased tPA mRNA levels and tPA activity in
Cdk5 cKO1 mice [10] and because neurons are known to
release tPA and activate microglia through annexin II [43],
we therefore evaluated here whether tPA plays a major
role in neuroinflammation and neuronal loss observed on
Cdk5 cKO mice. Additionally, it was reported that tPA
can exert neurotoxic effects in a catalytic-independent
way by activating the ERK1/2 signaling pathway and that
this molecular mechanism could be responsible for the
neuronal death induced in mouse hippocampal neurons
after Aβ treatment [44]. Moreover, the same group also
reported that Aβ treatment of tPA deficient glial cells re-
sults in a dramatic reduction of inflammation analyzed by
TNF-α expression [45]. Here, we generated dKO mice
that lack tPA in all cells and Cdk5 in forebrain neurons. In
these mice, we found a partial rescue in astrogliosis, but
not in microgliosis. We also observed increased CD68
mRNA levels and increased Iba1 positive cells, markers of
microgliosis, in dKO mice. In contrast, it was reported
that tPA treatment did not increase Iba1 expression on
microglia from mouse spinal cord [46], suggesting an
unknown mechanism of microglia activation caused by a
deficiency of tPA. Finally, we found elevated levels of in-
flammatory cytokines in dKO mice in comparison with
control mice, suggesting that the increased expression of
tPA observed in the Cdk5 cKO1 mice does not contribute
significantly to the pathological process that leads to neu-
roinflammation, neuronal loss and early lethality.
Conclusion
We have demonstrated that tPA does not play a major
role in the etiology of neuroinflammation seen in Cdk5
cKO mice; however, the treatment with pioglitazone sig-
nificantly reduced the microgliosis, astrogliosis, and neur-
onal loss and improved the neurological deficit in Cdk5
cKO mice suggesting a beneficial effect of this PPARγ
agonist in treating neurodegenerative diseases.
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Additional file 1: Figure S1. Generation of Cdk5 cKO2, tPA KO mice.
Cdk5 floxed (Cdk5f/f) mice were crossed with tPA knockout mice (tPA KO)
to generate Cdk5f/f; tPA+/− mice. In addition, Cdk5+/− mice [7] were
crossed with either CamKIIα-Cre+ [17] and tPA KO mice to generate
Cdk5+/−; CamKIIα-Cre+ and Cdk5+/−; tPA KO mice, respectively. Lately,
Cdk5+/−; CamKIIα-Cre+ mice were crossed either with Cdk5f/f; tPA+/− and
Cdk5+/−; tPA KO mice to generate Cdk5f/-; CaMKIIα-Cre+; tPA+/− and
Cdk5+/−; CamKIIα-Cre+; tPA+/−. Finally, these mice were crossed to
generate Cdk5f/-; CamKIIα-Cre-; tPA+/− (control mice), Cdk5f/-;
CamKIIα-Cre+; tPA+/− (Cdk5 cKO2 mice) and Cdk5f/-; CamKIIα-Cre+;
tPA−/− (dKO mice).
Additional file 2: Figure S2. Inflammation proceeds neuronal loss in
Cdk5cKO mice. (A, B) IHC analysis of coronal brain sections of P21 day-old
mice. Sections of cerebral cortex (A) and hippocampus (B) from control
and Cdk5 cKO1 mice were stained with antibodies for NeuN, GFAP and
Iba1. Scale bar = 100 μm. (C-E) Bar graphs of average cell densities of
neuron (C), activated astrocytes (D) and microglia (E) in each brain region
of Cdk5 cKO1 mice and littermate controls at P21. (F, G) IHC analysis of
coronal brain sections of P30 day-old mice. Sections of cerebral cortex (F)
and hippocampus (G) of the control and Cdk5 cKO1 mice were stained
with antibodies for NeuN, GFAP and Iba1. Scale bar = 100 μm. (H-J) Bar
graphs of average cell densities of neurons (H) activated astrocytes (I)
and microglia (J) in each brain region of Cdk5 cKO1 mice and littermate
controls at P30. **P < 0.01; ***P < 0.001 (t-test).
Additional file 3: Figure S3. Evaluation of degenerative neurons and
neuron size on coronal brain section of Cdk5 cKO1 mice. (A)
Degenerative neurons were evaluated by amino-cupric silver stain of
different areas of the brain control and Cdk5 cKO1 mice at P30. Increase
number of amino-cupric silver positive cells (brown) on cerebral cortex
and striatum of Cdk5 cKO1 in comparison with control mice. (B)
Representative coronal sections stained with a red fluorescent Nissl stain
(NeuroTraceTM530/615) to evaluated neuronal size in control and Cdk5
cKO1 mice. No difference in neuronal size was found in CA1 pyramidal
neurons between Cdk5 cKO1 and control littermates at P30. Bar graphs
indicate average of neuronal size of neurons from control and Cdk5
cKO1 mice.
Additional file 4: Figure S4. PPARγ agonist pioglitazone treatment
suppresses neuroinflammation and reverses neuronal loss in Cdk5 cKO1
mice at P90. (A) Survival curves for untreated and treated Cdk5 cKO1
mice from P30 to P90. Survival rate for treated mice (n = 4) is better than
that of untreated mice (n = 4). (P = 0.029 in Log-rank test and P = 0.030 in
Wilcoxon test). (B) Average body weights of untreated (n = 4) and treated
(n = 3) Cdk5 cKO1 male mice and littermate male Cdk5f/f (control) mice
(n = 4) at P90. *P < 0.05; **P < 0.01 (t-test). (C, D) IHC cortex sections
of the control, untreated, and treated Cdk5 cKO1 mice o (C) and
hippocampus (D) at P90. Coronal sections from these mice were stained
with antibodies for NeuN, GFAP and Iba1. Scale bar = 100 μm. (E-G) Bar
graphs indicate average cell densities of neurons (E), activated astrocytes
(F) and microglia cells (G) in control, untreated and treated Cdk5 cKO1
mice at P90. *P < 0.05; **P < 0.01; ***P < 0.001 between control versus
Cdk5 cKO1. †P < 0.05; ‡P < 0.01; §P < 0.001 between untreated versus
treated.
Additional file 5: Movie S1. Partial improvement in abnormal limb
retraction and tremors in Cdk5 conditional knockout mice treated with
Pioglitazone.
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